NCT01121705View on ClinicalTrials.gov

Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)

PHASE3CompletedINTERVENTIONAL

Enrollment

360

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Chronic Hepatitis

Interventions

DRUG

Peg Interferon alpha2b + Ribavirin

"B 1 I or II: Experimental~variable duration of treatment group according with RVR. In case of RVR present patients will be treated for 12 weeks. Patients without RVR will be treated for 24 (B1I) or 36 (B1II)weeks: different duration of treatment for patients without RVR"

Trial Locations (8)

Unknown

Ospedale Civile, Sassari

Ospedale Civile, Canossa

Ospedale Casarano, Casarano

"IRCCS De Bellis", Castellana Grotte

"Ospedale Garibaldi", Catania

"Ospedale S.Camillo", Rome

Università Cattolica Sacro Cuore Roma, Rome

Ospedale Venosa, Venosa

All Listed Sponsors

lead

Casa Sollievo della Sofferenza IRCCS

OTHER

NCT01121705 - Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3) | Biotech Hunter | Biotech Hunter